Featured Content

H. Jack West, MD
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)

Drugs Show Promise for Some Advanced Lung Cancers

(U.S. News & World Report/HealthDay News) Apr 29, 2015 - Two experimental drugs may help patients whose lung cancer has become resistant to the latest available treatments, separate studies say.

Commentary: Both AZD9291 and CO-1686 are clearly active drugs for at least patients with T790M mutation positive acquired resistance...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Cancer Drug Spending Tops $100 Billion, Up 10% in a Year

(CNBC) May 5, 2015 - That's up more than 10 percent from 2013 and up from $75 billion five years earlier, according to a new report.
read article »

Aetna to Stop Covering Routine Use of Power Morcellator

(MarketWatch/Wall Street Journal) May 5, 2015 - Aetna Inc. will stop covering routine use of the laparoscopic power morcellator this month, marking the most direct blow from a major health insurer to a surgical tool that regulators determined can spread hidden cancer in women.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Drugs Show Promise for Some Advanced Lung Cancers (U.S. News & World Report/HealthDay News)

Both AZD9291 and CO-1686 are clearly active drugs for at least patients with T790M mutation positive acquired resistance...posted by: H. Jack West, MD

How Big Can Merck's Keytruda Be In Lung Cancer? (Forbes)

As impressive as the results for pembrolizumab are in this selected population, it's worth bearing in mind two...posted by: H. Jack West, MD

Oncologist Highlights Primary Reasons for the High Cost of Cancer Care (AJMC)

All factors mentioned contribute to the high cost of oncology care. Interesting that price is only 15% of the...posted by: Winston Wong, PharmD

Angry Over Drug Prices, More States Push Bills for Pharma to Disclose Costs (Wall Street Journal/Pharmalot blog)

The cynical part of me is thinking that while it is fine to support pricing transparency from the drug manufacturer,...posted by: Winston Wong, PharmD

Payers and Providers Discuss Pros and Cons of Oncology Payment Reform (AJMC)

I do not think we have even begun to determine when Oncology reimbursement reform should even look like. There...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Seattle Genetics has 3 new jobs posted.


Bayer has 11 jobs posted.


Circassia has 1 job posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
FATE +8.30%
NLNK +5.28%
ONCY +2.87%
NBS -12.77%
MGNX -8.61%
ARRY -7.98%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: Q2 2015
Company: Exelixis
Product: cabozantinib

Date: August 11, 2015
Company: Roche / Genentech & Exelixis
Product: cobimetinib

Date: Q3 2015
Company: AstraZeneca PLC
Product: Iressa® (gefitinib)

See All OBR Radar items»